TARA experienced a dramatic 69.5% decline in cash reserves from $162.8M to $49.7M while operating losses deepened significantly and share count increased by 47%.
The massive cash burn combined with worsening operating losses (-$35.8M to -$56.4M operating cash flow) raises immediate liquidity concerns for this biotech company. The 47% increase in outstanding shares (36.8M to 54.1M) suggests substantial dilutive equity raises were needed to fund operations, which explains how stockholders' equity increased despite mounting losses.
TARA's financial position deteriorated markedly with cash declining 69.5% to $49.7M while operating losses expanded across all metrics - R&D expenses surged 34.5%, operating losses widened 31.3% to -$64.5M, and operating cash outflow increased 57.4% to -$56.4M. Despite growing total assets 15.4% and stockholders' equity 17.5%, the 47% share count increase indicates significant dilutive financing was required. The combination of accelerating cash burn, deepening losses, and substantial shareholder dilution signals mounting financial stress for investors.
Cash declined 69.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Operating cash flow fell 57.4% — earnings quality concerns; investigate working capital changes and non-cash items.
Capital expenditure jumped 49.2% — major investment cycle underway; assess returns on deployment.
R&D investment increased 34.5% — signals commitment to future product development, though near-term margin impact.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 28.8% — review whether driven by operations, interest costs, or non-recurring items.
Equity base grew 17.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 15.4% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →